

# Nonparametric Reinforcement Learning for Survival Outcomes

Hunyoung Cho, Shannon T. Holloway, and Michael R. Kosorok\*

University of North Carolina at Chapel Hill  
and North Carolina State University

April 3, 2023



UNC

GILLINGS SCHOOL OF  
GLOBAL PUBLIC HEALTH

- (Statistical) precision medicine
  - Data-driven decision support for treating patients in the presence of heterogeneity (dynamic treatment regimes or DTRs)
  - Treatment can include drug choice, administrative actions, dosing, timing, potentially modifiable risk factors, and/or other potentially beneficial actions to the patients
  - Must be reproducible and generalizable (empirically and inferentially valid)

- Observable Constituents:
  - Tailoring variables ( $X$ )
  - Choice of treatments and/or potentially modifiable risk factors ( $A$ )
  - Vector of outcomes or utilities ( $R$ )
  - Could be multiple ( $X, A, R$ ) triples over time for each patient
- Dynamic Treatment Regime (DTR):
  - Single decision: make a single recommendation for treatment
  - Multiple decision: make a series of interdependent recommendations
  - Continual monitoring: for diabetes, mHealth

- Role of Heterogeneity in the data:
  - Heterogeneity of patients is beneficial (essential) for good precision medicine analysis so that estimated treatment rules are broadly applicable
  - Need heterogeneity of treatment assignment (either naturally or by design) in the data so we can determine best treatment under a variety of situations

- Dynamic Treatment Regime:
  - $\pi(X)$  gives recommended  $A$  to maximize  $R$  in future patients
  - Regression: model  $R$  as a function of  $X$  and  $A$  ( $Q(X, A) = E[R|X, A]$  is the “value”), with interaction between  $X$  and  $A$  being most important
  - Policy estimation: directly estimate  $\pi(X)$  without necessarily needing  $Q(X, A)$  (e.g., outcome weighted learning)
  - Prediction versus prescriptive decision support:
    - Suppose  $R = f(X) + Ag(X) + e$ , where bigger  $R$  is better and  $A = \{0 \text{ or } 1\}$
    - We only care about  $g(x)$ , since rule  $\pi(X) = \{1 \text{ if } g(X) > 0, 0 \text{ otherwise}\}$  yields optimal decision
    - A focus on prediction may yield information inefficiency through focus on  $f(X)$  instead of  $g(X)$

# The Multi-Decision Setting

- The multi-decision setting:
  - Two or more opportunities for treatment decisions (i.e., cancer treatment involving multiple lines of chemotherapy, other chronic diseases, etc.).
  - Interventions can affect patients in multiple ways
    - Immediate effects (proximal)
    - Delayed effects (distal): sometimes the best treatment is initially harmful but sets the patient up for a better response to certain future treatments

- The basic ingredients:
  - The data:  $(X_1, A_1, R_1, \dots, X_T, A_T, R_T)$ , where
    - $X_1 \in \mathcal{X}_1$  denotes baseline information
    - $X_t \in \mathcal{X}_t$  denotes interim information collected during treatment stages  $t = 2, \dots, T$
    - $A_t \in \mathcal{A}_t$  denotes treatment and
    - $R_t$  denotes proximal outcome measured after treatment at stage  $t$ ,
    - for  $t = 1, \dots, T$ .
  - Define  $H_1 = X_1$  and  $H_t = (H_{t-1}, A_{t-1}, R_{t-1}, X_t)$  so that  $H_t$  is the available patient history at time  $t$  before new action.
  - The data used for analysis is now  $(H_1, A_1, R_1, \dots, H_T, A_T, R_T)$ .

## The Bellman equation and Q-learning

- $Q_k^\pi(h, a) = E[R_k + Q_{k+1}^\pi(H_{k+1}, A_{k+1} = \pi_{k+1}(H_{k+1})) \mid H_k = h, A_k = a],$   
 $k = K - 1, K - 2, \dots, 1,$

where  $\pi$  is a certain policy that maps  
 $\mathcal{H} \equiv (\mathcal{H}_1, \dots, \mathcal{H}_k) \mapsto \mathcal{A} \equiv (\mathcal{A}_1, \dots, \mathcal{A}_k).$



## The Bellman equation and Q-learning

- $Q_k^\pi(h, a) = E[R_k + Q_{k+1}^\pi(H_{k+1}, A_{k+1} = \pi_{k+1}(H_{k+1})) \mid H_k = h, A_k = a],$   
 $k = K - 1, K - 2, \dots, 1,$

where  $\pi$  is a certain policy that maps  
 $\mathcal{H} \equiv (\mathcal{H}_1, \dots, \mathcal{H}_k) \mapsto \mathcal{A} \equiv (\mathcal{A}_1, \dots, \mathcal{A}_k).$


- Q-learning recursively finds the optimal policy as  
 $\pi_k^*(h) = \arg \max_{a \in \mathcal{A}_k} Q_k^{\pi^*}(h, a),$   $k = K, K - 1, \dots, 1.$

# Q-learning for the Multi-Decision Setting

- Regress  $R_T$  onto  $(H_T, A_T)$  to obtain an estimate of  $E[R_T | H_T = h, A_T = a]$ , denoted  $\hat{Q}_T(h, a)$ .
- For each individual, compute  $\hat{R}_T = \sup_{a \in \mathcal{A}_T} \hat{Q}_T(H_T, a)$ .
- Proceeding backwards from  $t = T - 1$  to  $t = 1$ , do the following:
  - Regress  $R_t + \hat{R}_{t+1}$  onto  $(H_t, A_t)$  to obtain an estimate of  $E[R_t + \hat{R}_{t+1} | H_t = h, A_t = a]$ , denoted  $\hat{Q}_t(h, a)$ .
  - For each individual, compute  $\hat{R}_t = \sup_{a \in \mathcal{A}_t} \hat{Q}_t(H_t, a)$ .


The estimated optimal dynamic treatment regime is then  $\hat{\pi}_t(h_t) = \arg \max_{a \in \mathcal{A}_t} \hat{Q}_t(h_t, a)$ , for  $t = 1, \dots, T$ .

# Dynamic treatment regimes (DTR) for survival outcomes



Question: Can we find a set of dynamic rules that maximizes the survival outcomes?


# Dynamic treatment regimes (DTR) for survival outcomes



Question: Can we find a set of dynamic rules that maximizes the survival outcomes?

A potential solution: Q-learning.

# Dynamic treatment regimes (DTR) for survival outcomes



Question: Can we find a set of dynamic rules that maximizes the survival outcomes?

A potential solution: Q-learning.


# Dynamic treatment regimes (DTR) for survival outcomes



Question: Can we find a set of dynamic rules that maximizes the survival outcomes?

A potential solution: Q-learning.

# Dynamic treatment regimes (DTR) for survival outcomes



Question: Can we find a set of dynamic rules that maximizes the survival outcomes?

A potential solution: Q-learning.

Challenges:

- Number of stages differ (failure or dropout before all planned visits).
- How to do backward recursion for survival data?

How was censoring handled in the literature?

Goldberg and Kosorok (2012)

- modified data without loss or addition of information
  - The time increments ( $R_k = T_k$ ) after censoring/failure are left as zero
  - The history after censoring/failure is set as  $H_k = \emptyset$
  - The actions after censoring/failure are randomly drawn.



How was censoring handled in the literature?

Goldberg and Kosorok (2012)

- modified data without loss or addition of information
  - The time increments ( $R_k = T_k$ ) after censoring/failure are left as zero
  - The history after censoring/failure is set as  $H_k = \emptyset$
  - The actions after censoring/failure are randomly drawn.
- Use Q-learning with the complete ‘pseudo’ data

How was censoring handled in the literature?

Goldberg and Kosorok (2012)

- modified data without loss or addition of information
  - The time increments ( $R_k = T_k$ ) after censoring/failure are left as zero
  - The history after censoring/failure is set as  $H_k = \emptyset$
  - The actions after censoring/failure are randomly drawn.
- Use Q-learning with the complete ‘pseudo’ data
- Censoring is handled by inverse probability of censoring weighting (IPCW).

How was censoring handled in the literature?

Goldberg and Kosorok (2012)

- modified data without loss or addition of information
  - The time increments ( $R_k = T_k$ ) after censoring/failure are left as zero
  - The history after censoring/failure is set as  $H_k = \emptyset$
  - The actions after censoring/failure are randomly drawn.
- Use Q-learning with the complete 'pseudo' data
- Censoring is handled by inverse probability of censoring weighting (IPCW).

However, *independent censoring* was assumed.

Several other relevant methods.

method	$ \mathcal{A}_k $	failure time	policy class	censoring	criterion
Goldberg et al (2012)	finite	nonparametric	flexible	$C \perp T_k$	$E[T]$
Huang et al (2014)	finite	AFT	linear	CI	$E[T]$
Simoneau et al (2019)	2	AFT	linear	CI	$E[T]$
Jiang et al (2017)	2	PH	linear	CI	$S(t)$

- $|\mathcal{A}_k|$ , the number of treatment arms at stage  $k$ .
- criterion, the target value being optimized.
- AFT, accelerated failure time; PH, proportional hazards; CI, conditional independence.
- $E[T]$ , mean (truncated) survival time;  $S(t)$ , survival probability at time  $t$ .

Several other relevant methods.

method	$ \mathcal{A}_k $	failure time	policy class	censoring	criterion
Goldberg et al (2012)	finite	nonparametric	flexible	$C \perp T_k$	$E[T]$
Huang et al (2014)	finite	AFT	linear	CI	$E[T]$
Simoneau et al (2019)	2	AFT	linear	CI	$E[T]$
Jiang et al (2017)	2	PH	linear	CI	$S(t)$
<i>new</i>	finite	nonparametric	flexible	CI	$E[T], S(t)$

- $|\mathcal{A}_k|$ , the number of treatment arms at stage  $k$ .
- criterion, the target value being optimized.
- AFT, accelerated failure time; PH, proportional hazards; CI, conditional independence.
- $E[T]$ , mean (truncated) survival time;  $S(t)$ , survival probability at time  $t$ .


The proposed method.

- Nonparametric Q-function estimation (random forest).
- Censoring mechanism: covariate-conditionally independent.
- The outcome of interest =  $\phi(S)$ , some function of the survival probability;  
 $\phi(S)$  can be the (truncated) mean survival time ( $E[T \wedge \tau]$ ) or survival probability at a certain time  $t$  ( $S(t)$ ).

The proposed method.

- Nonparametric Q-function estimation (random forest).
- Censoring mechanism: covariate-conditionally independent.
- The outcome of interest =  $\phi(S)$ , some function of the survival probability;  
 $\phi(S)$  can be the (truncated) mean survival time ( $E[T \wedge \tau]$ ) or survival probability at a certain time  $t$  ( $S(t)$ ).
- Backward recursion  $\Rightarrow$  Slightly more general than Q-learning


# DTR for survival outcomes - Notation



- $K$  treatment stages  
( $A_k \in \mathcal{A}_k, k = 1, 2, \dots, K$ ).
- $(T_k, U_k)$  are the times to failure and the next treatment at Stage  $k$ .
- $V_k = T_k \wedge U_k$ .
- $\gamma_k = 1(T_k \leq U_k)$ .
- $L_k =$  "the remaining life" after start of Stage  $k$ .
- $B_k =$  time elapsed before  $k$ .



# DTR for survival outcomes - Notation




- $L_k$  can be recursively written as,

$$L_k = V_k + (1 - \gamma_k)L_{k+1} \quad \text{for } k < K - 1.$$

- $K$  treatment stages  
( $A_k \in \mathcal{A}_k$ ,  $k = 1, 2, \dots, K$ ).
- $(T_k, U_k)$  are the times to failure and the next treatment at Stage  $k$ .
- $V_k = T_k \wedge U_k$ .
- $\gamma_k = 1(T_k \leq U_k)$ .
- $L_k =$  “the remaining life” after start of Stage  $k$ .
- $B_k =$  time elapsed before  $k$ .

# DTR for survival outcomes - Notation



- $L_k$  can be recursively written as,

$$L_k = V_k + (1 - \gamma_k)L_{k+1} \quad \text{for } k < K - 1.$$

- $L_k^*$  = the remaining life, were the optimal treatments given in later stages ( $k' > k$ ).

- $K$  treatment stages ( $A_k \in \mathcal{A}_k$ ,  $k = 1, 2, \dots, K$ ).
- $(T_k, U_k)$  are the times to failure and the next treatment at Stage  $k$ .
- $V_k = T_k \wedge U_k$ .
- $\gamma_k = 1(T_k \leq U_k)$ .
- $L_k$  = “the remaining life” after start of Stage  $k$ .
- $B_k$  = time elapsed before  $k$ .






- Backward recursion: Start from stage  $K, K - 1, \dots, 1$ .
- For stage  $k$ ,
  - Estimate  $S_k$  (the “cumulative” survival curves):  $\hat{S}_k(t | H_k, A_k = a)$
  - Find  $\hat{\pi}_k$  (the stage  $k$  decision rule):  
 $\hat{\pi}_k(h) = \arg \max_a \phi(\hat{S}_k(\dots | H_k = h, a))$
  - Augmentation: Add the previous stage length to the optimized curve when  $\gamma_{k-1} = 0$ .  $X_{k-1} + L_k^*$  where  $L_k^* \sim \hat{S}_k^{\hat{\pi}_k}$ .
- The final rule:  $\hat{\boldsymbol{\pi}} = (\hat{\pi}_1, \hat{\pi}_2, \dots, \hat{\pi}_K)^\top$ .

The terminal stage estimator ( $k = K$ )


- $S_K(t|H_K, A_K)$ : the 'terminal stage' survivor function of  $L_K(= T_K)$ .
- Estimated using random survival forest.
- The optimal ITR estimator for stage  $K$  is,

$$\hat{\pi}_K(h_K) = \arg \max_{a \in \mathcal{A}_K} \phi(\hat{S}_k(t - B_k | H_K = h_K, A_K = a)).$$

# DTR for survival outcomes - illustration




# DTR for survival outcomes - illustration






# DTR for survival outcomes - illustration




# DTR for survival outcomes - illustration



For earlier stages. Consider stage  $k < K$ .

- stage length  $X_k$  at  $k$  is augmented by  $\hat{S}_{k+1}^*$ .  
This is done by using  $\hat{S}_{k+1}^*(t - X_k | H_k, A_k)$  for each individual.  
(For those censored during stage  $k$ , no augmentation is needed.)
- Now the survival distribution of  $L_k$  is estimated using the stochastically augmented intervals  $\{\hat{S}_{k+1}^*(t - X_{k,i} | H_{k,i}, A_{k,i})\}_i$ .

# DTR for survival outcomes - Generalized random forests



- Generalized random survival forests are used.  
Modified splitting rules, Modified Kaplan-Meier at terminal nodes
- Properties: uniform consistency under certain regularity conditions.
- Simulations validate theory, is effective in example application.

## Theorem

*Assuming the conditions that follow, the value  $\mathcal{V}$  of the estimated optimal dynamic treatment regime,  $\hat{\pi}$ , is consistent for the truth. I.e.,*

$$|\mathcal{V}(\hat{\pi}) - \mathcal{V}(\pi_*)| \rightarrow_P 0,$$

*as  $n \rightarrow \infty$ , where the value ( $\mathcal{V}(\pi)$ ) is either the restricted mean survival time ( $E[T^\pi \wedge \tau]$ ) or the survival probability at a certain time ( $S^\pi(t_0)$ ).*

# DTR for survival outcomes - Theoretical results, assumptions

Assumptions for each stage  $k$ :

- 1 Stable unit treatment value assumption SUTVA
- 2  $A_k \perp T_k^a \mid H_k, \forall a \in \mathcal{A}_k$  sequential ignorability
- 3  $\Pr(A_k = a \mid H_k = h) > L_1 \quad \forall a, h, \exists L_1 > 0.$  positivity
- 4  $\Pr(U_k < T_k \wedge C_k \mid \mathbf{h}) > M, \quad \forall \mathbf{h} \in \mathcal{H}_k, \exists M > 0.$  completion
- 5  $|S_k(t \mid \mathbf{h}_1) - S_k(t \mid \mathbf{h}_2)| \leq L_S \|\mathbf{h}_1 - \mathbf{h}_2\|,$  Lipschitz continuity  
 $|G_k(t \mid \mathbf{h}_1) - G_k(t \mid \mathbf{h}_2)| \leq L_G \|\mathbf{h}_1 - \mathbf{h}_2\|,$   
 $\forall \mathbf{h}_1, \mathbf{h}_2, \exists 0 < L_S, L_G < \infty.$
- 6  $1/\zeta \leq f_{H_k}(h) \leq \zeta$  weak dependence
- 7  $n_{\min} \rightarrow \infty$  with  $\frac{\log n \log \log n}{n_{\min}} \rightarrow \infty$  terminal node size
- 8 Regular and random-split trees less greedy splitting

- We use error bounding methods given in Murphy (2005) and Goldberg and Kosorok (2012) to bound the DTR error by the uniform accuracy of the nonparametric survival estimator at each  $1 \leq k \leq K$ .
- Specifically, we show that

$$\mathcal{V}(\pi_*) - \mathcal{V}(\hat{\pi}) \leq \sum_{k=1}^K c_k(\phi) \times \sqrt{\sup_{\mathbf{h}_k, a_k, t \in [0, \tau]} \left| \hat{S}_k(t | \mathbf{h}_k, a_k) - S_k(t | \mathbf{h}_k, a_k) \right|},$$

where  $c_k(\phi)$  are constants that depend on the reward function  $\phi$ .

- We then establish the needed uniform consistency and convergence rates.

# Uniform consistency of survival estimators - Theoretical results

## Theorem

*Suppose the assumptions hold. Let  $\hat{\mathbf{S}} = (\hat{S}_1, \dots, \hat{S}_2, \dots, \hat{S}_K)$  be the sequence of the generalized random survival forest estimators of  $\mathbf{S} = (S_1, \dots, S_k, \dots, S_K)$  such that the  $k$ th stage random survival forest is built based on  $\hat{S}_{k+1}$  for  $k = 1, 2, \dots, K - 1$ . Then,*

$$\sup_{t \in [0, \tau], \mathbf{h} \in \mathcal{H}_k, k \in \{1, 2, \dots, K\}} |\hat{S}_k(t | \mathbf{h}) - S_k(t | \mathbf{h})| \rightarrow 0,$$

*in probability as  $n \rightarrow \infty$ .*



# Survival consistency outline of proof

- Results follow from uniform consistency of each  $\hat{S}_k$ , beginning with  $k = K$  and going backwards to  $k = 1$ .
- We use Z-estimator consistency based on identifiability of the estimating equation (i.e., showing that if the expected Z-function, evaluated at  $\theta_n$ , goes to zero uniformly over the index, then this forces  $\|\theta_n - \theta_0\| \rightarrow 0$ ) combined with uniform consistency of the empirical Z-function (see, e.g., Theorem 2.10 of Kosorok, 2008).
- We use VC-dimension bounded kernel representations of the random forests based on axis-aligned rectangles to obtain consistency of the empirical Z-function.

# Uniform convergence rate of survival estimators - Theoretical results

## Theorem

Suppose the assumptions hold plus a few additional assumptions. Then, for any  $k = 1, 2, \dots, K$ , there exists an  $1 \leq n_0 < \infty$  such that for all  $n > n_0$  the following holds with probability  $\geq 1 - \frac{3(K-k+1)}{\sqrt{n}}$ :

$$\begin{aligned} & \sup_{t \leq \tau, \mathbf{h}_k} |\hat{S}_k(t; \mathbf{h}_k) - S_k(t; \mathbf{h}_k)| \\ & \leq \sum_{l=k}^K \frac{11}{c_1} \sqrt{\frac{\log\left(\frac{n}{n_{\min}}\right) \{\log(d_l n_{\min}) + 3 \log \log(n)\}}{n_{\min} \log((1-\alpha)^{-1})}} \\ & \quad + \zeta L_S \left\{ \frac{2n_{\min}}{n} \right\}^{\frac{\log((1-\alpha)^{-1})}{\log(\alpha^{-1})} \frac{0.991\varphi}{d_l}}, \end{aligned}$$

where the constants come from the assumptions.

# Uniform convergence rate of survival estimators - Theoretical results, cont.

## Theorem

*In the context of the previous theorem,  $n_{\min}$  and the other tuning parameters can be chosen so that, for some  $\eta > 0$ ,*


$$\sup_{t \leq \tau, \mathbf{h}_k} |\hat{S}_k(t; \mathbf{h}_k) - S_k(t; \mathbf{h}_k)| = O_P(n^{-\eta}),$$

*and*

$$\mathcal{V}(\pi_*) - \mathcal{V}(\hat{\pi}) \leq O_P(n^{-\eta/2}).$$

Thus the convergence rates are polynomial in  $n$ .



# Simulation results



from Cho, Holloway and Kosorok (2020)

- We applied these methods to an acute myeloid leukemia clinical trial with survival as an outcome (Wahed & Thall, 2013; Xu et al, 2016).
- 210 patients were randomized to frontline treatment (4 possibilities) followed by salvage treatment (2 classes) adaptively chosen by clinicians based on patient status.

# Leukemia clinical trial results, cont.



from Cho, Holloway and Kosorok (2020)

- Clinicians appear to be making treatment selection effectively.
- Composite criterion
  - Optimize  $S(t)$  first and, if tied, use  $E(T)$  as the second criterion.
- Non-Markov assumption: History matters.  
However, the disease dynamics need to be stationary within a treatment stage.

# DTR for survival outcomes–Collaboration, status, and Acknowledgement

- We thank Dr. Donglin Zeng for the discussion of the composite criterion.
- Data credits to Drs. Peter F. Thall, Abdus S. Wahed, and Yanxun Xu (the leukemia data).
- Partial support by grant P01 CA142538 from the National Cancer Institute.
- In press with *Biometrika*. Available on [arXiv](#).
- R package [dtrSurv](#) on CRAN.

